Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and Follicular Lymphoma By admin / 06/15/2017
Updated Results of a Multicenter Phase I/IB Study of Umbralisib (TGR-1202) in Combination with Ibrutinib in Patients with Relapsed or Refractory MCL or CLL By admin / 06/14/2017
Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL By admin / 06/05/2017
Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study By admin / 06/03/2017
TGR-1202– A novel PI3K-delta inhibitor that differentially regulates T cells in CLL By admin / 05/15/2017
TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL: Updated Results of a Multicenter Phase I/Ib Study By admin / 05/15/2017
KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy By admin / 03/05/2017
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial By admin / 02/21/2017
A phase 1/2 trial of ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab By admin / 12/16/2016
